paying for prevention – why, how, and when the case of preventing diabetes ronald t. ackermann,...

21
Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief Institute for Healthcare

Upload: zachary-ortiz

Post on 27-Mar-2015

216 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Paying for Prevention –

Why, How, and When

The Case of Preventing Diabetes

Ronald T. Ackermann, MD, MPHIndiana University School of MedicineRegenstrief Institute for Healthcare

Page 2: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Pre-Diabetes – • 65 million Americans

(30% of all adults)• Progression to diabetes

5 – 15% per year

Diabetes – The Tip of the Iceberg…Diabetes – • 21 million Americans

Page 3: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Lifetime Risk of Diabetes by BMI

0%10%20%30%40%50%60%70%80%90%

White Female

White Male

Black Female

Black Male

Hispanic Female

Hispanic Male

<18.518.5 - 24.925 - 29.930 - 34.935+

Predicted lifetime prevalence of diabetes for 18 year old today; Narayan et al., 2007

Page 4: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Escalating Costs of Diabetes

$205$241

$338

$0

$100

$200

$300

$400

Bil

lio

ns

$U

S

2007 2010 2020

Year

Projected Total Direct Medical Costs for Patients with Diabetes, Year 2007 $US (Billions); ADA 2008 (based on methods from Hogan, 2003)

Page 5: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Policy Goal

Population-Level

Diabetes Prevention!

•How much can / should the healthcare system invest toward this goal?

•In which persons will these resources have the biggest impact?

•How should resources be distributed across different “at-risk” groups?

Page 6: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Obesity Programs that Work – Targeting the Highest Risk

Diabetes Prevention Program (DPP) >3,000 overweight / obese adults with Pre-diabetes (IGT) High short-term risk for diabetes, CVD, and costs 3-arm randomized trial

Intensive Lifestyle Intervention Metformin (Diabetes medication) Placebo (Basic advice)

Outcomes Prevention or delay of Diabetes Costs and cost-effectiveness

Page 7: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

DPP Lifestyle Intervention

16 “core” one-on-one meetings ~1hr/week Monthly lifestyle maintenance visits Safe and Effective

11 pounds (~5%) weight loss = 58% in diabetes Improved control of other CVD risk factors No major AE’s Cost-effective - Health Payer: $1,100/QALY

Page 8: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

People have pre-diabetes for 8-10 years before getting diabetes

Routine blood tests can identify pre-diabetes Intensive interventions reduce diabetes

development & reduce future costs Cannot assume that lower intensity

interventions with same goals will have the same results

Diabetes Can be Prevented!

Page 9: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Diabetes Costs – With Primary Prevention

$205$241

$209

$338

$260

$0

$100

$200

$300

$400

Bil

lio

ns

$US

2007 2010 2020

Year

Projected

With DPP

Projected Total Direct Medical Costs for Patients with Diabetes, Year 2007 $US (Billions); ADA 2008

Costs for Diabetes $130 B lower over 13 years

Page 10: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Population-based Diabetes Prevention

Coverage of fasting glucose tests for persons at risk

Pre-diabetes management

Earlier detection and management of T2DM

Tight CVDRF Control & Follow-up

Identify adults with diabetes risk factors (EHR; Claims)

Lower Diabetes & CVDRF Burden Lower PMPM cost; Improved outcomes

DPP Coverage Benefit

Page 11: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Elements of Cost-Effective Diabetes Prevention

Evidence / goal Healthcare Community

Target adults with pre-diabetes X

Provide structured lifestyle program to achieve 5-7% weight loss X

Link to health plan / employer payment (physician initiated) X

Provide ongoing behavior support at least monthly X

Page 12: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Partnered Approach for Prevention

Healthcare

Glucose testingRisk/benefit assessment (safe?)Prescriptive advice (role for meds?)Gateway to reimbursement

Formal Programs

CommunityPopulation Resources

EnvironmentEducation by Schools & Media Lower intensity programsRisk assessment opportunitiesReciprocal

InteractionsPersonnelExperienceFacilitiesContact

Page 13: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

DPP Coverage Benefit Structure

Patient

Primary Provider

Recognized Diabetes Prevention Program

Certified Instructor

Health Plan Coverage?

Diabetes

CVDRF Outcomes

CostsSponsoring Organization

ADA

Community Partner

Page 14: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Community Linkage Partner – The YMCA?

2,600 YMCAs in the U.S. 42M U.S. families within 3 miles of a Y Strong history of disseminating structured

programs nationally (arthritis) Operate to achieve cost recovery only Policy to turn no person away for inability to

pay for a program (financial assistance)

Page 15: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Group Delivery of DPP

Offers program to a group of 10 – 12 Enhances social support and accountability Lowers direct intervention costs by 50-85% Allows cost-savings within 2 years of coverage

for health plan that pays intervention fees (greater ROI if cost-sharing)

Page 16: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Minimizing Program Costs

Cost Category Original DPP No IncentivesGroup Format

Group Format –

YMCA Instructor

Personnel $794 $794 $156 $131

Supplies $11 $11 $11 $11

Incentives $123 $10 $10 $10

Overhead $548 $548 $108 $91

Total $1,476 $1,363 $284 $243

Page 17: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

BUT CAN A CERTIFIED COMMUNITY VENDOR (THE YMCA) ACHIEVE 5% WEIGHT LOSS IN ADULTS WITH PRE-DIABETES?

Page 18: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

DEPLOY Study (NIH)

Community-based randomized trial Test the feasibility and effectiveness of

training YMCA employees to deliver a group-based version of the DPP lifestyle intervention in YMCA branch facilities

Page 19: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

DEPLOY Outcomes - % Weight Reduction

*p-values comparing Group DPP to Brief Advice

Page 20: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Bottom Line DPP lifestyle programs…

Cut diabetes development in half Are cost-saving when delivered efficiently in

community settings PMPM for Group DPP

Yr 1 - $21 Yrs 2 to 13 - $11

Time to ROI for payer <2 years By 2020, U.S. healthcare system would manage

113M fewer member-months of adult diabetes

Page 21: Paying for Prevention – Why, How, and When The Case of Preventing Diabetes Ronald T. Ackermann, MD, MPH Indiana University School of Medicine Regenstrief

Questions?

Ronald T. Ackermann, MD, MPHIndiana University School of MedicineRegenstrief Institute for [email protected]

Thanks to CDC-RTI Economic Evaluation Workgroup and the DEPLOY Study Team